These are the primary and secondary endpoints:
Primary Outcome Measures :
Secondary Outcome Measures :
- Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA) [ Time Frame: Baseline to Week 24 ]
- Proportion of participants gaining 15 or more ETDRS BCVA letters [ Time Frame: Baseline to Week 24 ]
- Area under the ETDRS BCVA over time curve [ Time Frame: Baseline to Week 24 ]
- Change in central subfield thickness (CST) on spectral domain optical coherence tomography (SD-OCT) [ Time Frame: Baseline to Week 24 ]
- Change in intra-retinal fluid and sub-retinal fluid on SD-OCT [ Time Frame: Baseline to Week 24 ]
- Proportion of participants losing 15 or more letters (on ETDRS BCVA chart) [ Time Frame: Baseline to Week 24
- Forums
- ASX - By Stock
- Ann: Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
These are the primary and secondary endpoints: Primary Outcome...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
87.0¢ |
Change
-0.025(2.79%) |
Mkt cap ! $1.064B |
Open | High | Low | Value | Volume |
88.5¢ | 88.5¢ | 85.8¢ | $1.327M | 1.530M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 22858 | 86.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
87.0¢ | 24250 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 21741 | 0.865 |
10 | 40203 | 0.860 |
13 | 99924 | 0.855 |
9 | 71430 | 0.850 |
5 | 130879 | 0.845 |
Price($) | Vol. | No. |
---|---|---|
0.870 | 24341 | 14 |
0.875 | 55802 | 13 |
0.880 | 59702 | 11 |
0.885 | 22024 | 5 |
0.890 | 147340 | 6 |
Last trade - 11.09am 08/10/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |